ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 253 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q4 2020. The put-call ratio across all filers is 0.32 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $348 | -7.4% | 64,118 | +14.9% | 0.00% | 0.0% |
| Q2 2023 | $376 | +27.5% | 55,805 | +67.0% | 0.00% | 0.0% |
| Q1 2023 | $295 | -3.3% | 33,421 | -16.0% | 0.00% | 0.0% |
| Q4 2022 | $305 | -99.8% | 39,808 | +86.7% | 0.00% | – |
| Q3 2022 | $152,000 | +300.0% | 21,319 | +359.8% | 0.00% | – |
| Q2 2022 | $38,000 | -44.1% | 4,637 | 0.0% | 0.00% | – |
| Q1 2022 | $68,000 | -47.7% | 4,637 | 0.0% | 0.00% | – |
| Q4 2021 | $130,000 | -29.0% | 4,637 | -13.6% | 0.00% | – |
| Q3 2021 | $183,000 | -16.8% | 5,370 | 0.0% | 0.00% | -100.0% |
| Q2 2021 | $220,000 | +2.3% | 5,370 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $215,000 | -40.8% | 5,370 | -12.9% | 0.00% | 0.0% |
| Q4 2020 | $363,000 | +46.4% | 6,167 | +20.6% | 0.00% | 0.0% |
| Q3 2020 | $248,000 | +0.8% | 5,112 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $246,000 | – | 5,112 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 2,377,665 | $12,958,274 | 12.23% |
| Eagle Health Investments LP | 1,214,860 | $6,620,987 | 1.46% |
| Matrix Capital Management Company, LP | 11,572,590 | $63,070,616 | 0.76% |
| Aristotle Atlantic Partners, LLC | 3,058,206 | $16,667,223 | 0.67% |
| VIKING GLOBAL INVESTORS LP | 29,993,708 | $163,465,709 | 0.66% |
| Pier Capital, LLC | 719,067 | $3,918,915 | 0.63% |
| DDD Partners, LLC | 783,697 | $3,385,571 | 0.49% |
| ARK Investment Management | 11,509,308 | $62,725,728 | 0.48% |
| Nikko Asset Management Americas, Inc. | 6,570,939 | $35,680,199 | 0.43% |
| Triatomic Management LP | 102,889 | $560,745 | 0.39% |